Clinical Trials

PhaseBio is exploring the potential benefit of our investigational therapies in clinical trials in order to confirm their mechanisms of action in humans, to investigate their side effects and to understand the characteristics of those patients most likely to benefit.

Our lead product candidate, PB2452, is a novel ticagrelor reversal agent and we recently completed a Phase 1 dose escalation clinical trial of PB2452 in healthy subjects who had been pre-dosed with ticagrelor.

PB1046, our long-acting VIP analogue, is currently being evaluated in a Phase 2b trial in PAH patients.

PhaseBio strives to work closely with patients and the scientific and regulatory communities to rapidly advance our pipeline and identify new therapeutic applications that may benefit from our ELP biopolymer technology.